Therapeutic vaccination with tumor cells that engage CD137. (Q35071688)

6 August 2017

1 reference

title

Therapeutic vaccination with tumor cells that engage CD137. (English)

1 reference

6 August 2017

Karl Erik Hellstrom

1

1 reference

PubMed ID

12601523

6 August 2017

Ingegerd Hellstrom

series ordinal

2

1 reference

6 August 2017

8 February 2003

1 reference

Journal of Molecular Medicine

6 August 2017

1 reference

6 August 2017

81

1 reference

6 August 2017

71-86

1 reference

6 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s00109-002-0413-8

6 August 2017

0 references

cites work

Demonstration of cell-bound and humoral immunity against neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Cell-mediated and humoral immune reactions to human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Sensitization to tumour-associated antigens in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Tumour-associated lymphocyte cytotoxicity superimposed on "spontaneous" cytotoxicity in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Relationship of human natural lymphocyte-mediated cytotoxicity to cytotoxicity of breast-cancer-derived target cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Can co-stimulated tumor immunity be therapeutically efficacious?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Therapeutic vaccination for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Immunity to oncogenic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

New paths in human cancer serology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Progress in human tumour immunology and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Tumor antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Active immunization against cancer with dendritic cells: the near future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Progression of human breast cancers to the metastatic state is linked to hydroxyl radical-induced DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

A mouse mutant p53 product recognized by CD4+ and CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Immunological determinants of polyoma virus oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Human tumor antigens recognized by T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Specific carcinoembryonic antigens of the human digestive system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

MUC-1 epithelial tumor mucin-based immunity and cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Inhibition of leukocyte migration by human breast-cancer-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Use of proteomic patterns in serum to identify ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Acquisition of immunologic self-tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

IMMUNOLOGY OF EXPERIMENTAL TUMORS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

The TRAIL to selective tumor death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

CTLA-4 can function as a negative regulator of T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

CTLA-4: new insights into its biological function and use in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Surface expression of CD28 single chain Fv for costimulation by tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Tumor-induced immune dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Enhancement of tumor outgrowth by tumor-associated blocking factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Suggestive Evidence That the “Blocking Antibodies” of Tumor-Bearing Individuals May Be Antigen-Antibody Complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Surrogate antigen processing mediated by TAP-dependent antigenic peptide secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Tumor cells express FcgammaRI which contributes to tumor cell growth and a metastatic phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Immune complexes (IC) down-regulate the basal and interferon-gamma-induced expression of MHC class II on human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Activation of suppressor T cells by tumour cells and specific antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

The implications of embryonic gene expression in neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Expression of Fas ligand in liver metastases of human colonic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Identification of human cancers deficient in antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Antigen-processing machinery breakdown and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Expression patterns of cancer testis antigens in testicular germ cell tumors and adjacent testicular tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Chemotherapy for trophoblastic disease: current standards

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Reciprocal activating interaction between natural killer cells and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Dendritic and natural killer cells cooperate in the control/switch of innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Antiangiogenic gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Roles of heat-shock proteins in innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Global control of hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Feline leukaemia virus: a review of immunity and vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Fas antigen (CD95) in pure erythroid cell line AS-E2 is induced by interferon-gamma and tumor necrosis factor-alpha and potentiates apoptotic death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Danger signals: SOS to the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Genetically engineered tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Dendritic cell vaccination for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

21 January 2018

12 December 2020

Apoptotic, non-apoptotic, and anti-apoptotic pathways of tumor necrosis factor signalling

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Cellular and Humoral immunity to Different Types of Human Neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0413-8

Specificity and longevity of antitumor immune responses induced by B7-transfected tumors

21 January 2018

1 reference

12 December 2020

Cancer vaccines: a road map for the next decade

1 reference

12 December 2020

Proceedings: Escape from immune destruction by the host through shedding of surface antigens: is this a characteristic shared by malignant and embryonic cells?

1 reference

12 December 2020

Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.

1 reference

12 December 2020

Nitric-oxide-dependent systemic immunosuppression in animals with progressively growing malignant gliomas

1 reference

12 December 2020

Cancer vaccines: challenges and potential solutions

1 reference

12 December 2020

Tumor antigens recognized by T lymphocytes

1 reference

12 December 2020

Demonstration of cell-mediated immunity to human neoplasms of various histological types

1 reference

12 December 2020

Cell-Mediated Immunity to Tumor Cells

1 reference

12 December 2020

Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.

1 reference

12 December 2020

Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation.

1 reference

12 December 2020

Toward a genetic analysis of tumor rejection antigens.

1 reference

12 December 2020

Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts

1 reference

12 December 2020

Transplanted carcinoma in an immunosuppressed patient

1 reference

12 December 2020

Identification of cancer antigens: impact on development of cancer immunotherapies

1 reference

12 December 2020

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

1 reference

12 December 2020

Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival

1 reference

12 December 2020

CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes

1 reference

12 December 2020

Cellular and humoral immune responses to human urinary bladder carcinomas

1 reference

12 December 2020

Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma

1 reference

12 December 2020

Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells

1 reference

12 December 2020

Exploiting dendritic cells to improve vaccine efficacy

1 reference

12 December 2020

Express yourself or die: peptides, MHC molecules, and NK cells

1 reference

12 December 2020

Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.

1 reference

12 December 2020

Down-regulation of the antitumor immune response.

1 reference

12 December 2020

Inhibition of leukocyte migration by tumor-associated antigens in soluble extracts of human malignant melanoma

1 reference

12 December 2020

CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen

1 reference

12 December 2020

Demonstration of antibodies against human malignant melanoma by immunofluorescence.

1 reference

12 December 2020

TAP expression provides a general method for improving the recognition of malignant cells in vivo

1 reference

12 December 2020

Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.

1 reference

12 December 2020

Comparative analysis of CD137 and LPS effects on monocyte activation, survival, and proliferation

1 reference

12 December 2020

Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death

1 reference

12 December 2020

Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides

1 reference

12 December 2020

Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients

1 reference

12 December 2020

Specific desensitization of resistance against a syngeneic methylcholanthrene-induced sarcoma in C3Hf mice

1 reference

12 December 2020

Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal

1 reference

12 December 2020

Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host

1 reference

12 December 2020

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

1 reference

12 December 2020

CD40 preferentially costimulates activation of CD4+ T lymphocytes

1 reference

12 December 2020

Nonvirus-associated antigens in virus-induced mouse mammary tumors.

1 reference

12 December 2020

Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity

1 reference

12 December 2020

Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases

1 reference

12 December 2020

Antigen-specific purification of blocking factors from sera of mice with chemically induced tumors

1 reference

12 December 2020

Immunologic rejection of human cancer transplanted with a renal allograft

1 reference

12 December 2020

IFN-gamma-induced recognition of the antigen-processing variant CMT.64 by cytolytic T cells can be replaced by sequential addition of beta 2 microglobulin and antigenic peptides

1 reference

12 December 2020

Human melanoma cells do not express Fas (Apo-1/CD95) ligand

1 reference

12 December 2020

Papillomaviruses in human cancer

1 reference

12 December 2020

Cell-mediated suppression of tumor immunity has a non-specific component. I. Evidence from transplantation tests

1 reference

12 December 2020

1 reference

12 December 2020

A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance?

1 reference

12 December 2020

Expression of MAGE genes in testicular germ cell tumors

1 reference

12 December 2020

CD40 ligation for immunotherapy of solid tumours

1 reference

12 December 2020

A humanized anti--4-1BB monoclonal antibody suppresses antigen-induced humoral immune response in nonhuman primates

1 reference

12 December 2020

Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity

1 reference

12 December 2020

Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16

1 reference

12 December 2020

Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.

1 reference

12 December 2020

Identification of CD137 as a potent monocyte survival factor

1 reference

12 December 2020

Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules

1 reference

12 December 2020

Advanced testicular cancer: update for urologists

1 reference

12 December 2020

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

1 reference

12 December 2020

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

12 December 2020

The role of the CD28 receptor during T cell responses to antigen

1 reference

12 December 2020

The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy

1 reference

12 December 2020

Progressive depletion of peripheral B lymphocytes in 4-1BB (CD137) ligand/I-Ealpha)-transgenic mice

1 reference

12 December 2020

Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway

1 reference

12 December 2020

Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC.

1 reference

12 December 2020

4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy

1 reference

12 December 2020

Characterization of human colon cancer antigens recognized by autologous antibodies

1 reference

12 December 2020

Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines

1 reference

12 December 2020

Tumor vaccines--a reality at last?

1 reference

12 December 2020

A novel role for TGF-beta and IL-10 in the induction of immune privilege

1 reference

12 December 2020

Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells

1 reference

12 December 2020

High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer

1 reference

12 December 2020

Immunity to methylcholanthrene-induced sarcomas

1 reference

12 December 2020

Transplantation methods as a tool for detection of tumor-specific antigens

1 reference

12 December 2020

B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes

1 reference

12 December 2020

Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin

1 reference

12 December 2020

Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells.

1 reference

12 December 2020

Cellular Immunity Against Tumor Antigens

1 reference

12 December 2020

An overview of the MAGE gene family with the identification of all human members of the family

1 reference

12 December 2020

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma

1 reference

12 December 2020

T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer

1 reference

12 December 2020

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1 reference

12 December 2020

Oncogene-associated tumor antigens as targets for immunotherapy

1 reference

12 December 2020

Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells

1 reference

12 December 2020

Modulation of antitumor immune responses

1 reference

12 December 2020

Relationship between Fas-ligand expression on carcinoma cell and cytotoxic T-lymphocyte response in lymphoepithelioma-like cancer of the stomach

1 reference

12 December 2020

Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice

1 reference

12 December 2020

Reactivity of lung cancer patients in leukocyte migration inhibition assays to 3-M potassium chloride extracts of fresh tumor and tissue-cultured cells derived from lung cancer

1 reference

12 December 2020

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors

1 reference

12 December 2020

The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.

1 reference

12 December 2020

Advances in management of high-risk gestational trophoblastic tumors.

1 reference

12 December 2020

Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16.

1 reference

12 December 2020

The identification of cancer antigens: impact on the development of cancer vaccines.

1 reference

12 December 2020

MAGE-A4, a germ cell specific marker, is expressed differentially in testicular tumors

1 reference

12 December 2020

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

12 December 2020

10.1007/S00109-002-0413-8

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12601523